Nuclear hormone receptor variants: their role in malignancy and progression to hormone resistance in cancer

M Sluyser1

  • 1Division of Tumour Biology, The Netherlands Cancer Institute.

Acta Endocrinologica
|January 1, 1991
PubMed

Insights

Structural variants of nuclear hormone receptors can promote cancer by interfering with normal receptor function or activating genes independently. These variants also contribute to hormone resistance in cancers like breast and prostate.

Area of Science:

  • Molecular biology
  • Oncology
  • Endocrinology

Background:

  • Structural variants of nuclear hormone receptors are identified in tumor tissues.
  • These variants are implicated in cancer development and progression.

Purpose of the Study:

  • To elucidate the oncogenic potential of nuclear hormone receptor structural variants.
  • To understand their role in hormone-independent gene activation and hormone resistance.

Main Methods:

  • Review of experimental evidence on nuclear hormone receptor variants.
  • Analysis of proposed oncogenic mechanisms.

Main Results:

  • Nuclear hormone receptor variants can act as dominant negative oncogenes, suppressing normal receptor function.
  • Variants can activate hormone-responsive genes without hormonal signaling.

Conclusions:

  • Structural variants of nuclear hormone receptors possess oncogenic potential through dominant-negative effects or hormone-independent gene activation.
  • These mechanisms contribute to oncogenesis and the development of hormone resistance in cancers such as breast and prostate cancer.

Related Concept Videos

Intracellular Hormone Receptors01:08

Intracellular Hormone Receptors

Lipid-soluble hormones diffuse across the plasma and nuclear membrane of target cells to bind to their specific intracellular receptors. These receptors act as transcription factors that regulate gene expression and protein synthesis in the target cell
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...